Albert Kildani | executive |
Stephen Davis | executive |
Brendan Teehan | executive |
Doug Williamson | executive |
Mark Schneyer | executive |
Tessa Romero | analyst |
Ashwani Verma | analyst |
David Hoang | analyst |
Charles Duncan | analyst |
Ritu Baral | analyst |
Lee Hung | analyst |
Gregory Renza | analyst |
Ami Fadia | analyst |
Uy Ear | analyst |
Marc Goodman | analyst |
Yatin Suneja | analyst |
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results Conference Call. My name is Abigail, and I will be your coordinator for today.[Operator Instructions] I would now like to turn the presentation over to Al Kildani, Senior Vice President of Investor Relations and Corporate Communications at ACADIA. Please proceed.
Good afternoon, and thank you for joining us on today's call to discuss ACADIA's fourth quarter and full year 2023 earnings results.
Joining me on the call today from Acadia are Steve Davis, our Chief Executive Officer, who will provide some opening remarks, followed by Brendan Teehan, our Chief Operating Officer and Head of Commercial, who will discuss our strong commercial franchises, DAYBUE and NUPLAZID.